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Abstract
When studying incidence of pain conditions such as temporomandibular disorders (TMDs),
repeated monitoring is needed in prospective cohort studies. However, monitoring methods
usually have limitations and, over a period of years, some loss to follow-up is inevitable. The
OPPERA prospective cohort study of first-onset TMD screened for symptoms using quarterly
questionnaires and examined symptomatic participants to definitively ascertain TMD incidence.
During the median 2.8-year observation period, 16% of the 3,263 enrollees completed no follow-
up questionnaires, others provided incomplete follow-up, and examinations were not conducted
for one third of symptomatic episodes. Although screening methods and examinations were found
to have excellent reliability and validity, they were not perfect. Loss to follow-up varied according
to some putative TMD risk factors, although multiple imputation to correct the problem suggested
that bias was minimal. A second method of multiple imputation that evaluated bias associated with
omitted and dubious examinations revealed a slight underestimate of incidence and some small
biases in hazard ratios used to quantify effects of risk factors. Although “bottom line” statistical
conclusions were not affected, multiply-imputed estimates should be considered when evaluating
the large number of risk factors under investigation in the OPPERA study.
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Perspective—These findings support the validity of the OPPERA prospective cohort study for
the purpose of investigating the etiology of first-onset TMD, providing the foundation for other
papers investigating risk factors hypothesized in the OPPERA project.
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The high quality of evidence from prospective cohort studies is attributable to 2 features of
the study design. First, by quantifying the likelihood of developing an illness, prospective
cohort studies address a critical question asked by individuals who have yet to develop it:
“Am I likely to get the illness?” At a population level, the same prognostic information is
essential when predicting the impact of interventions on the public health. Second, because
exposure to hypothesized risk factors is measured prior to illness onset, prospective cohort
studies establish a temporal sequence between putative cause and effect. This is a cardinal
criterion for causal inference.18
Despite these attributes, prospective cohort studies are relatively uncommon compared to
other study designs investigating etiology, primarily because longitudinal data collection is
logistically complex, time-consuming, and expensive. Prospective cohort studies of chronic
pain face additional challenges5 because symptom episodes often are transient and
recurrent.3,8,9,27,36-38 Furthermore, because long-term recall of such episodes is unreliable,17
prospective cohort studies are likely to underestimate incidence of chronic pain when it is
recalled only at a single follow-up assessment conducted years after enrollment.
Problems created by poor recall of pain episodes can be addressed by repeated monitoring
throughout the study’s period of follow-up. The strategy is epitomized in clinical trials
where daily diaries monitor pain intensity and symptoms. Daily monitoring is not feasible
for studies with lengthy follow-up, and neither is it necessary in population-based studies
where the focus is on people’s experience of discrete episodes of pain. Instead, monthly or
quarterly (3-monthly) monitoring is appropriate. For example, in a UK-based study,8
questionnaires were administered monthly for up to 6 months after enrollment of 342 adult
patients who had low back pain. During follow-up, 43% reported pain that varied between
months. In a U.S. population-based study of 1,336 adolescents,9 questionnaires administered
once every 3 months for up to 3 years evaluated back pain, headache, stomach pain, and
facial pain. Forty percent developed 1 or more types of pain, although only 12% had
persistent pain. In both studies, intermittent episodes of pain would have been overlooked if
only a single follow-up assessment had been conducted at the end of the study.
Repeated monitoring has associated problems of its own, including loss to follow-up, which
is almost inevitable in population-based studies. When follow-up assessments are missing,
biased estimates are likely if the data are analyzed using conventional methods of complete-
case analysis.22 If loss to follow-up is unrelated to putative risk factors, estimated
associations between risk factors and incidence are biased toward the null. A more serious
problem occurs when loss to follow-up varies according to putative risk factors. Under such
conditions, estimates of association become biased in directions that cannot readily be
determined.
This paper reports methodological details of a prospective cohort study of first-onset
temporomandibular disorder (TMD), a painful musculoskeletal condition of the face and
jaws. The study was part of the project entitled Orofacial Pain: Prospective Evaluation and
Risk Assessment (OPPERA). One aim of this paper is to describe the study’s methods of
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enrollment, follow-up, and ascertainment of TMD incidence. The other aim is to evaluate
the degree to which loss to follow-up and related problems in data collection might have
affected estimates of the study’s 2 main outcome measures: TMD incidence and hazard
ratios of association between putative risk factors and TMD incidence.
Methods
The OPPERA prospective cohort study was designed to investigate the etiology of first-
onset, painful TMD. Relationships among components of the OPPERA project are depicted
in Supplementary e-Figure 1. Six other papers in this volume present associations between
putative risk domains and TMD incidence. Previous publications24 reported findings from
the OPPERA baseline case-control study of chronic TMD. Methods of baseline data
collection for this prospective cohort study were provided in one of those papers32 and are
summarized below to provide a background to methods used for follow-up and
measurement of TMD incidence.
Institutional review boards at each study site approved study procedures, and participants
provided signed, informed consent. The OPPERA study is being conducted under the
auspices of a Certificate of Confidentiality (NIDCR-06-17) between the National Institutes
of Health and Dr. William Maixner, Program Director of OPPERA. The Certificate protects
the privacy of research participants.
Target Population and Selection of Study Participants
The target population was community-based volunteers aged 18 to 44 years with no
significant history of TMD who lived or worked near 4 recruitment sites that were selected
to provide a demographically diverse sample of U.S. adults: Baltimore, MD; Buffalo, NY;
Chapel Hill, NC; and Gainesville, FL. Between May 2006 and November 2008, potential
study participants were recruited using advertisements, e-mails, and flyers. The goal was to
enroll an inception cohort, defined as people with no current or previous experience of
TMD. An initial set of inclusion and exclusion criteria were administered by telephone
screening interviews. Inclusion criteria were all 7 of 1) age 18 to 44 years, 2) planning on
living in the area for the next 2 years, 3) fluent in written and spoken English, 4) reported
having never been diagnosed with TMD, 5) reporting no significant history of orofacial pain
(ie, no orofacial pain in the month before enrollment and, prior to that period, no more than
4 days of oro-facial pain per month), 6) reporting <5 headaches/month in the 3 months
before enrollment, and 7) no reported use of a night guard or occlusal splint (Fig 1).
Exclusion criteria were any 1 of 13 conditions: 1) traumatic facial injury or surgery on the
face or jaw within the 6 months preceding enrollment, 2) currently receiving orthodontic
treatment, 3) pregnant or nursing, 4) kidney failure or renal dialysis, 5) heart disease or heart
failure, 6) chronic respiratory disease that is not controlled with medication, 7) hypertension
that is not controlled with medication, 8) epilepsy or medication to control grand mal
seizures, 9) hyperthyroidism, 10) diabetes that is not controlled with medication or diet, 11)
drug or alcohol abuse, 12) psychiatric disorders or conditions that have required
hospitalization, or 13) chemotherapy or radiation therapy.
Our justification for selecting 18- to 44-year-olds was that we expected them to have a
higher incidence of TMD than other age groups,7 and therefore represent a high-priority
group from a public health perspective. Nearby residency was an important requirement for
efficient conduct of the study, and English-language proficiency was necessary because
many of the standardized questionnaires were not available in other languages. A negative
history of significant TMD symptoms or treatment was necessary to create an inception
cohort in which development of first-onset TMD could be monitored. Given the potential
overlap of TMD and headache symptoms, we likewise excluded people with frequently
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occurring headache. Current orthodontic treatment and recent facial injury or surgery were
exclusion criteria because we felt that thorough baseline oral examinations would be
compromised in such people. Likewise, people with the other health-related conditions were
excluded either because the investigators felt the conditions might invalidate components of
the baseline clinical assessments or because standard operating procedures of the dental
schools at each study site precluded elective dental care for such people.
After screening, potential participants attended a study site’s research clinic where 2
additional inclusion criteria were determined: 1) pain reported in the examiner-defined
orofacial region for no more than 4 days in the prior 30 days and 2) absence of both TMD
myalgia and arthralgia. The latter 2 criteria were determined by trained and calibrated
examiners using a protocol based on the Research Diagnostic Criteria for TMD10 and
described in detail elsewhere.29 In summary, the study participant’s orofacial region was
defined as examiners touched the following anatomic areas bilaterally: temporalis,
preauricular, masseter, posterior mandibular, and submandibular areas. Examiners asked
structured questions about any pain history in this defined orofacial region. They also
evaluated signs of painful TMD during jaw movement and digital palpation of study
participant’s orofacial structures. The origin of any pain reported during jaw movement and
palpation was classified by the examiner into 1 or more of 5 anatomic locations, each
considered bilaterally: temporalis, masseter, lateral pterygoid, submandibular and posterior
mandibular, and temporomandibular joint (TMJ). TMD was classified for study participants
who reported both 1) pain in the orofacial region for ≥5 days in the prior 30 days and 2) pain
in ≥3 muscles locations (myalgia) or in ≥1 TM joints (arthralgia) during jaw movement or
orofacial palpation. Although participants with examiner-verified TMD were excluded from
the inception cohort, individuals were retained in the inception cohort if they reported pain
during examination procedures but did not report a history of pain for ≥5 days in the prior 30
days.
Baseline Interview, Questionnaires, Examination, Physiologic Testing, and Biospecimen
Collection
Prior to the clinic visit, study participants completed psychosocial questionnaires—either
paper forms sent by postal mail or equivalent versions online.12 During the clinic visit,
additional psychosocial and health status questionnaires were completed. In addition to the
clinical orofacial assessments of TMD, examiners evaluated study participants’ tenderness
to neck and body palpation.29 Quantitative sensory testing performed after the examination
measured responses to standardized noxious stimuli.16 Autonomic function was monitored
at rest, during orthostatic challenge, and during the Stroop color-word test and pain-affect
test.25 Anthropometric measurements were recorded, and a 20 mL sample of peripheral
blood was collected by venipuncture for subsequent DNA purification and genotyping.35
Examiner Training, Calibration, and Reliability
Prior to study initiation, clinical examiners from each study site were trained and jointly
calibrated by 2 expert dentists (Y.G. and R.O.). Y.G. served as the reference examiner
throughout the study, and R.O. monitored examiner performance for adherence to protocol.
In a separate session, examiners conducted at least 10 blinded, replicated examinations of
non-OPPERA volunteers: 1 examination in each pair was conducted by the OPPERA
examiner and the other by the reference examiner. Volunteers in these reliability studies
were selected to yield an approximate 2:1 ratio of TMD cases and noncases. Similar
calibration and reliability sessions were repeated approximately annually after study
initiation. Data from the blinded, replicate examinations were analyzed for interexaminer
reliability computed using the Kappa statistic.
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Follow-Up Quarterly Health Update Questionnaires
At 3-monthly intervals after enrollment, study participants completed a quarterly health
update questionnaire that included screening questions about orofacial pain. In order to
capture an approximate 3-month period of symptoms, the questionnaire was imprinted with
an individualized reference date that was 13 weeks prior to the intended completion date.
Two weeks prior to the intended completion date, the questionnaire was sent to the study
participant with instruction to answer the questions on paper or online. Reminder e-mails
were sent 1 week before and on the day of the intended completion date.
Screening questions asked about pain symptoms and other health-related events in the
period since the reference date. The intended reporting period of 13 weeks varied in duration
because some respondents completed the quarterly health update earlier or later than
intended. Questions that screened for likely onset of TMD inquired about “headaches or
pain in your face, jaw, temples, in front of the ear, or in the ear” (hereafter “orofacial pain”)
during the reporting period. An orofacial symptom episode was defined when answers to
questions about density of orofacial pain symptoms met either of 2 criteria: 1) ≥5
consecutive days of orofacial pain per month for ≥2 months, with ≥1 day of orofacial pain in
the 2 weeks preceding questionnaire completion, or 2) ≥5 consecutive days of orofacial pain
in the month preceding questionnaire completion, with ≥5 days of orofacial pain in the 2
weeks preceding questionnaire completion. Reporting periods that did not meet this
threshold are referred to hereafter as “asymptomatic episodes.”
If a study participant did not complete any quarterly health updates within a 12-month
period or if their contact information became invalid, they were traced using an iterative
process. First, local site coordinators used available contact information, including alternate
point-of-contact information collected at enrollment, to locate study participants. If this
effort yielded no new contact information, the data coordination center traced participants
using a variety of professional epidemiologic tracing resources.
Study participants were paid a $5 incentive for each completed quarterly health update, with
an additional $10 bonus after completion of every fourth consecutive questionnaire.
Consistent completion of questionnaires over a 5-year period earned the participant an
additional $50 bonus.
Follow-Up Clinical Assessments and Classification of First-Onset TMD
Study participants reporting an orofacial symptom episode were asked to attend the research
clinic where examiners used the same baseline examination protocol to classify presence or
absence of TMD. In this way, participants were classified with first-onset TMD when they
met each of 2 criteria: 1) ≥5 days of pain during the preceding 30 days in TMD locations
specified by examiner and 2) examiner findings of pain in ≥1 temporomandibular joint(s)
(arthralgia) or in ≥3 muscle locations (myalgia) during jaw maneuver or palpation. Most of
the other measures recorded at baseline were repeated during these follow-up visits of
symptomatic study participants (Supplementary e-Table 1).
Follow-up clinical assessments were also conducted for a random sample of study
participants who had asymptomatic episodes (Supplementary e-Fig 1). It was a matched
sampling design that selected 1 asymptomatic participant at random to correspond with each
symptomatic participant. There were 4 matching criteria: 1) enrollment within 15 days of
one another, 2) enrollment at the same study site, 3) same gender, and 4) quarterly
questionnaires completed within 3 months of one another. One goal of examining
asymptomatic participants was to evaluate the quarterly health update’s negative predictive
value, defined as the percentage of asymptomatic episodes that were classified as noncases
of TMD during the subsequent examination. Most of the other measures recorded at baseline
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were repeated during these clinic visits that followed asymptomatic episodes
(Supplementary e-Table 1).
Most study participants who made follow-up visits attended the research clinic at the study
site where they were enrolled, although 6 participants were reexamined at a different study
site after relocating. In results reported here and elsewhere, the participant’s study site was
deemed to be the site at which they were enrolled.
Reliability of Follow-Up Screening Questionnaires
Consistency of responses to quarterly health updates was evaluated in a separate study of
test-retest reliability conducted at each of the study sites. Approximately equal numbers of
TMD cases and TMD-free controls were recruited. A total of 105 participants completed 2
quarterly health updates separated by an interval of 4 to 8 days. Kappa statistics were
computed as measures of test-retest reliability in classifying orofacial symptom episodes.
Quality Control and Quality Assessment of Classification of First-Onset TMD
Each follow-up examination was subjected to 3 steps in data quality control.32 All
examination forms were reviewed by an OPPERA expert dentist at each site to verify
consistency between findings and case classification and to evaluate any notes recorded by
the study examiner that might influence case classification. When required, a clinical review
panel was conducted by conference call; the panel was composed of expert dentists and the
OPPERA principal investigator expert in TMD case classification (R.O.). They reviewed
online copies of casebook forms and resolved instances of uncertain case classification.
Finally, a software algorithm used data from scanned examination forms to verify that TMD
case classification was consistent with findings for relevant muscles and joints recorded
during jaw movement and palpation procedures. Any discrepancies between the
algorithmically derived classification and the examiner’s classification were reviewed and
resolved by members of the expert pain panel.
Quality assessment of examination findings was undertaken annually by merging data from
quarterly health updates and examinations to compute negative and positive predictive
values. The latter was defined as the percentage of symptomatic episodes that were
classified as first-onset TMD during the subsequent examination. The findings were
reported to the OPPERA External Scientific Advisory Committee that monitored the study’s
progress.
Sample Size Determination for the Inception Cohort
OPPERA was designed with a target sample size of 3,200 enrolled study participants. This
was expected to yield 196 cases of first-onset TMD during a 3-year follow-up period,
assuming 30% loss to follow-up. The expectations were based on incidence and cohort
retention rates observed in a previous study conducted at the North Carolina study site.6
This target sample size was calculated to provide 80% statistical power to detect risk ratios
of at least 1.8 for risk predictors with as few as 15% of people in the high-risk category. This
was consistent with the magnitude of effect seen for genetic predictors in the previous North
Carolina study.6
Statistical Methods
The follow-up period for each study participant was computed as the time from enrollment
date to the first of 3 possible events: 1) date of the examination when first-onset TMD was
classified, 2) date of the last-completed quarterly health update for people who stopped
returning quarterly health updates before May 31, 2011, or 3) the census date used for this
analysis (ie, May 31, 2011). The first event represented an observed outcome whereas the
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other 2 events represent censoring. If a participant had gaps in follow-up where they failed
to complete a quarterly questionnaire, the period was nonetheless included in the
participant’s total period of follow-up, so long as a subsequent questionnaire was completed
prior to the census date. Additionally, it was assumed that the participant did not develop
TMD during any such gaps. Although the 260 incident cases continued to complete
quarterly health updates after developing TMD (Supplementary e-Fig 1), those observation
periods were not used in this analysis. Participants who were examined but found not to
have TMD likewise continued to complete quarterly health updates, and those observation
periods did contribute to this analysis.
Using these criteria, the average annual rate of first-onset TMD was calculated as the
number of people with first-onset TMD divided by the sum of follow-up periods. The result
was expressed as the percentage of people per annum (equivalent to the number of incident
cases per 100 person-years of follow-up). For descriptive purposes, an adjusted average
annual incidence was computed using a Poisson regression model that adjusted for study site
using the Buffalo study site as the referent.
To test hypotheses about associations between baseline risk factors and TMD incidence,
hazard ratios were computed using Cox proportional hazard regression models. Hazard
ratios, the relative difference in hazard rates between 2 groups, are a theoretical construct
because the hazard rate is an unobservable, instantaneous event rate as the duration of
follow-up approaches zero. However, hazard ratios are a good approximation of the
incidence rate ratio in a cohort study.31 Although incidence rate ratios can be modeled
statistically, Cox models require fewer statistical assumptions and therefore were adopted as
the standard method to test for associations with putative risk factors. Hereafter, we use the
term incidence when referring both to the annual incidence rate and the hazard rate.
For the Cox models, an incident case was regarded as an event; otherwise participants were
censored. Each participant’s follow-up period (defined above) was used as the time-to-event.
When the baseline risk factor was categorical, one category was nominated as the referent
and indicator variables represented each of the other categories. The requirement of
proportional hazards was evaluated for each putative risk factor by testing the null
hypothesis of no correlation between the scaled Schoenfeld residuals of the appropriate
coefficient and (Kaplan-Meier transformed) time.14 Quantile-quantile plots of the resulting
P values were generated and the false-discovery rate was computed to identify any
characteristics that departed markedly from the assumption of proportional hazards (Fig 2).
The conventional regression models described above can produce erroneous results when
there are certain patterns of missing data for variables used in the analysis. Specifically, if
the probability of having a missing value depends on the unobserved value, the data are said
to be “missing not at random.”22 Because conventional regression methods use only the
observed data, ignoring the pattern of missing data, the estimates therefore are generally
biased when the data are missing not at random. Only under carefully considered
assumptions can one obtain unbiased regression estimates without further corrections. Two
such conditions are the following: 1) the probability of having a missing value is
independent of the data (ie, “missing completely at random”) or 2) the probability of having
a missing value is independent of the missing values but may depend on the observed values
or on observed covariates (ie, “missing at random”). In practice, it is virtually impossible to
determine if the data truly are missing at random, so it is prudent to conduct sensitivity
analysis evaluating the impact of missing data.
Four types of sensitivity analysis were undertaken to evaluate potential bias associated with
incomplete follow-up. Baseline characteristics were first compared between participants
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who completed one or more quarterly health updates and participants who completed no
quarterly health updates (the latter are defined here as participants with complete loss to
follow-up). Differences were evaluated using Student’s t-test for continuous measures and
likelihood ratio chi-square tests for categorical measures. Quantile-quantile plots of the
resulting P values were generated for 4 risk factor domains hypothesized in the OPPERA
heuristic model24: psychosocial characteristics; quantitative measures of pain sensitivity;
cardiovascular measures of autonomic function; and clinical measures of pain and health
status. Within each domain, one characteristic most strongly associated both with cohort
retention and with TMD incidence was selected. Those 4 characteristics, together with age,
gender, race, and study site, were then used to classify participants in the inception cohort,
and 3 measures of cohort retention were compared between subgroups: 1) the percentage of
participants with complete follow-up was calculated for each subgroup and results were
compared using the chi-square test; 2) the probability of remaining in the cohort for at least
2 years was computed using the life-table method, and results were compared using the
likelihood ratio test of the survivor function; and 3) the median number of completed
quarterly health updates was computed and results were compared using the Brown-Mood
test for median scores. The latter 2 statistics, computed for participants who completed at
least 1 quarterly health update, were used as indicators of “partial” loss to follow-up.
The second type of sensitivity analysis used variables identified in the preceding analysis to
impute TMD incidence for participants with complete loss to follow-up. Hot deck multiple
imputation1 was performed, with the goal to create groups composed of people with similar
baseline characteristics (“hot decks”), within which observed outcomes from people with
follow-up data were used to impute likely outcome values for people with no follow-up data.
In principle,1 the characteristics used to create “similarity” within the hot-decks should be
characteristics that are associated both with loss to follow-up and with the outcome.
Five steps therefore were used in this method of imputation: 1) Demographic and baseline
risk factors identified in the preceding analysis were used in a multivariable binary logistic
model regression to predict odds of complete loss to follow-up for all participants in the
inception cohort. 2) Participants in the inception cohort were ranked according to the value
of the model’s linear predictor, from which 20 equal-sized strata were calculated, each with
a successively greater probability of complete loss to follow-up. 3) For each of the 521
participants completely lost to follow-up, 1 participant was sampled at random from among
all participants in the same stratum who provided follow-up data. The method used simple
random sampling with replacement. The sampled participant’s follow-up status (first-onset
TMD or censored) and period of follow-up were used as the imputed estimates for the
individual lost to follow-up. 4) The imputed records were added to the records from 2,737
participants who had follow-up data, creating a data set of 3,258 individuals with complete
information about TMD incidence and follow-up period. 5) Steps 3 and 4 were repeated 100
times, with independent random sampling in each replication. Incidence rates and hazard
ratios were calculated for each of the 100 replicated data sets. The 100 sets of results were
combined using the “mianalyze” procedure in SAS to generate valid estimates of rates, rate
ratios, and standard errors.
The third type of sensitivity analysis dealt with 2 problems that occurred in enumerating
incident cases: 1) follow-up examinations were not conducted for approximately one third of
symptomatic episodes, usually because the participant was unable or unwilling to attend the
research clinic for an examination; 2) case classifications made by one examiner (hereafter,
“examiner 4”) were deemed dubious. Specifically, as documented below, the examiner’s
case classifications produced a conspicuously greater positive predictive and a lower
negative predictive value than other examiners’ findings. The first problem likely
contributed to underenumeration of incident cases, whereas the second problem likely
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contributed to overenumeration. To quantify the net effect, a 2-stage, multiple imputation
procedure was developed. In the first stage, a binary logistic generalized linear mixed model
regression equation estimated the probability of examiner-verified TMD for all symptomatic
episodes that were followed by an examination, excluding examinations conducted by
examiner 4. Predictor variables were selected from the participant’s baseline characteristics
and their responses to the quarterly health update that initiated the examination. The logistic
regression parameters were applied to symptomatic episodes that were not followed by an
examination and to all episodes that were examined by examiner 4, yielding a predicted
probability of first-onset TMD for such episodes. Each episode’s predicted probability was
then used to generate 100 Bernoulli random variables (1 or 0) signifying an imputed incident
TMD case or noncase, respectively. The imputed case classifications were combined with
observed follow-up data, and incidence rates and hazard ratios were calculated for each of
the 100 replicated data sets. The 100 sets of results were combined using the “mianalyze”
procedure in SAS to generate valid estimates of rates, rate ratios, and standard errors. For a
more detailed description of the methodology used to impute for missing follow-up
examinations, see Brownstein et al.2
The fourth type of sensitivity analysis addressed the problem of false negatives from
quarterly health updates, defined as asymptomatic episodes that would have been classified
as cases of TMD had they been examined. When the proportions are expressed as
percentages, the false-negative rate equals 100 minus the negative predictive value. The
calculation was made using the observed negative predictive value from follow-up
examinations of the random sample of asymptomatic episodes, described above. The false-
negative rate was applied to nonexamined participants who reported asymptomatic episodes,
and the expected number of incident cases was added to the observed number of incident
cases to provide a single-imputed estimate of TMD incidence.
Results
Enrollment and Follow-Up
Between May 2006 and November 2008, 3,263 participants who did not have TMD were
enrolled into the inception cohort. At enrollment, 85% of participants (n = 2,770) reported
having never experienced orofacial pain, and the remaining 15% (n = 488) reported some
history of orofacial pain that was below the enrollment-exclusion threshold of ≥5 days per
month. Postenrollment audits found that 5 were ineligible, and they were excluded from all
analysis. Sixteen percent (n = 521) of participants were completely lost to follow-up
whereas the remaining 84% (n = 2,737) completed 1 or more quarterly health updates for a
total of 26,666 follow-up questionnaires. This represented a median of 10 quarterly health
updates per person, somewhat less than the median of 14 questionnaires per person that
would have been completed had there been no partial loss to follow-up prior to May 2011.
In fact, only 1,154 participants (42% of 2,737) completed all intended quarterly health
updates through May 2011. The shortfall between the number of intended questionnaires
through May 2011 and the number completed represented the degree of partial loss to
follow-up. The median shortfall was 3 questionnaires per person, with lower and upper
quartiles of 0 and 9 questionnaires, respectively. The median period of follow-up was 2.8
years per person (minimum = .2 years, maximum = 5.2 years) for a total of 7,403 person
years of follow-up.
During follow-up, there were 721 orofacial symptom episodes, of which 478 (66%) were
accompanied by examinations that classified 235 participants as cases of first-onset TMD.
Of the 25,945 quarterly health updates with asymptomatic episodes, 338 were selected at
random for examination, and 25 of the examinations (7%) were classified with first-onset
TMD. The interval between quarterly health update and examination varied from 0 to 85
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days (median = 14 days) for the 260 cases of first-onset TMD and from 0 to 87 days
(median = 23-days) for examinees who did not have TMD. Two thirds (70.4%) of the 260
incident cases reported having experienced TMD symptoms for 1 or 2 months in the 3-
month period prior to the examination, and 65% said that their symptoms occurred in
recurrent bouts.
Factors Associated With Cohort Retention
The percentage of participants retained in the cohort varied significantly according to
gender, race and study site, although not age (Table 1). Demographic groups and study sites
had correspondingly large differences in the probability of retention for 2 years and in the
number of completed quarterly health updates. For the full set of 157 baseline predictor
variables, at least 5 measures within each of the 4 risk factor domains were associated with
complete loss to follow-up to a degree that exceeded chance, as judged by quantile-quantile
plots (Fig 3). Summary statistics of all variables are presented in Supplementary e-Table 2
through Supplementary e-Table 5, showing that most ratios of mean values between the
group retained in the cohort and the group lost to follow-up varied between .7 and 1.3,
whereas most ratios of odds between the 2 groups varied between .5 and 1.7.
Based on these findings and associations with TMD incidence reported in other papers in
this volume, the following baseline predictor variables were selected for hot deck multiple
imputation: number of body sites that were tender to palpation (higher values were
associated with greater TMD incidence28), change in mean arterial blood pressure during the
Stroop emotional word task (higher values were associated with lower TMD incidence15),
pressure pain thresholds measured at the trapezius (higher values were associated with lower
TMD incidence15), and the Perceived Stress Scale (higher values were associated with
greater TMD incidence11). Variation in cohort retention across terciles of those variables is
summarized in Table 1. In some instances, the factor associated with greater cohort retention
(eg, number of tender body sites) was also associated with greater TMD incidence,28
whereas in other instances, there were opposing effects. For example, greater pressure pain
threshold, which was associated with greater cohort retention (Table 1), was associated with
lower TMD incidence.15
The 4 demographic variables were also selected for hot-deck imputation, based on findings
that greater age and African American race were associated with greater TMD incidence,
Asians had lower TMD incidence, and females had marginally greater TMD incidence than
males.33 When all 8 of the selected variables were evaluated in a multivariable binary
logistic regression model, each made at least a nominal contribution to predicting the
probability of complete loss to follow-up (Supplementary e-Table 6). The area under the
receiver operating characteristic curve was .69 based on this model, indicating that this set
of variables provided a reasonable level of discrimination between people retained in the
cohort and participants completely lost to follow-up. To illustrate, there was more than 2-
fold variation in TMD incidence rate among the 20 strata, ranked inversely according to
predicted probability of retention in the cohort (Supplementary e-Table 7). However, the
relationship between probability of retention and TMD incidence was not monotonic
because, as noted above, some factors had opposing directions of association with cohort
retention and TMD incidence (Supplementary e-Table 7).
Factors Associated With Examination Following TMD Symptom Episodes
From 721 symptom episodes, 478 examinations were completed. The percentage examined
did not vary significantly according to most of the demographic characteristics and baseline
risk predictors (Table 2). However, the probability of follow-up examinations varied
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significantly among study sites, and it was lowest for symptom episodes that occurred some
years after enrollment.
Outcomes From Examinations Following Symptomatic and Asymptomatic Quarterly
Health Updates
Of the 478 orofacial symptom episodes that were examined, 49.2% were classified as first-
onset TMD, and hence the positive predictive value of the screening questions was 49.2%
(Table 3). Conversely, 92.6% of the asymptomatic episodes were confirmed as noncases of
TMD when examined (hence, the negative predictive value was 92.6%). Positive predictive
value varied significantly according to age, race/ethnicity, and study site, whereas the
number of tender body sites was the only baseline risk factor associated with positive
predictive value. Nonspecific orofacial pain reported in the quarterly health update and time
since enrollment were both associated with positive predictive value. In most instances, the
same characteristics were associated with variation in negative predictive values.
Of greatest concern were the results from one examiner who registered 100% positive
predictive value but only 76.5% negative predictive value (Table 3, Examiner 4). These
values differed markedly from the results for other examiners, either at the same study site
or elsewhere, and indicated that the examiner was much more likely than other examiners to
classify participants as incident cases.
Reliability and Validity of Quarterly Health Updates
In test-retest reliability of the quarterly health update questionnaire, the kappa statistic for
reliability of symptom episodes was .83 (95% confidence limits [CLs] = .72, .95), indicating
excellent agreement. The quarterly health update’s positive predictive value of 49.2%
reported above indicated a high rate of false-positive screenings (Table 3, “All people”).
However, the screening questions had good overall validity when also considering the high
negative predictive value of 92.6%. This corresponded to sensitivity of 90.4% and
specificity of 56.3%. After dubious case classifications by examiner 4 were excluded, the
screening questions had positive predictive value of 39.7%, negative predictive value of
94.4%, sensitivity of 90.4%, and specificity of 54.1%.
Reliability of Examiners’ Classifications of TMD
The 7 study examiners were evaluated for reliability in TMD case classification at multiple
sessions during the 5-year duration of the study, yielding a total of 432 paired examinations
(Table 4). Kappa statistics ranged from .82 to 1.00, signifying excellent interexaminer
reliability between each of the study site examiners and OPPERA’s referent examiner. It
was noteworthy that examiner 4 had excellent interexaminer reliability in all 4 reliability
assessments through February 2009. (In August 2009, examiner 4 stopped working in the
study.)
Sensitivity Analysis Using Complete-Case and Multiply-Imputed Data Sets
In univariate analysis of the complete-case data set of 2,737 participants who completed at
least one quarterly health update, the TMD annual incidence rate was 3.5%. There were
statistically significant differences in incidence according to age, race/ethnicity, study site,
and all 4 baseline risk predictors, although not gender (Table 5).
An identical annual incidence rate of 3.5% was obtained using hot-deck, multiple imputation
which accounted for complete loss to follow-up (Table 5). The baseline characteristics noted
above using complete-case analysis were likewise associated with the imputed incidence
rate, whereas gender was not. Compared to the complete case analysis, hazard ratios differed
by no more than .2 in absolute value. The largest difference between the analytic methods
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was observed for the highest tercile of perceived stress, where the imputed hazard ratio of
1.77 (95% CLs = 1.31, 1.40) was lower than the complete-case hazard ratio of 1.96 (95%
CLs = 1.44, 2.66). In each instance where hazard ratios differed between the 2 methods, the
imputed ratio was closer to the null value of 1.0.
The second method of multiple imputation used parameters from the binary logistic
regression model that predicted TMD case classification for symptomatic episodes
(Supplementary e-Table 8). When applied to symptomatic episodes that were not examined
as intended, the incidence rate increased to 3.9% per annum (Table 5). Most of the
associations seen with the complete case analysis were similar in this imputed analysis, with
hazard ratios differing by no more than .1 in absolute value. Among the baseline risk factors,
the largest difference was observed for the highest category of body tenderness, where the
imputed hazard ratio of 1.48 (95% CLs = 1.10, 1.99) was lower than the complete-case
hazard ratio of 1.77 (95% CLs = 1.32, 2.37). For the autonomic measure, the imputed hazard
ratio was farther from the null compared to the complete-case hazard ratio, whereas for 1
category of pressure pain thresholds, the imputed hazard ratio was closer to the null
compared to the complete-case hazard ratio.
Single Imputation of Incidence to Account for False-Negative Rate of Asymptomatic
Quarterly Health Updates
Although the false-negative rate of quarterly health updates was low, it was greater than
zero. Although there were too few false negatives to model asymptomatic events, it seemed
unlikely that the probability of false negatives would be equivalent for successive,
asymptomatic events. This supposition was confirmed in univariate analysis of the data from
338 asymptomatic examinations deemed dependable (ie, excluding examiner 4): 107 of
those examinations were from people who had only 1 asymptomatic episode, whereas 180
examinations were from 90 people who reported 2 asymptomatic episodes. (The remaining
51 asymptomatic examinations were of participants who also had symptomatic
examinations.) The observed probability of clinically classified TMD was 11.2% for
participants with a single asymptomatic episode but only 4.4% for participants with 2
asymptomatic episodes. The latter is much lower than the expected probability of 21.1% that
would occur according to the binomial theorem if the probability of a false positive in the
second asymptomatic episode were equal to and independent of the probability for a single
asymptomatic episode.
The approach to single imputation therefore applied the observed probability of a single
false negative to the 190 participants who reported only a single, asymptomatic episode
during follow-up, but who did not have a follow-up examination by design. For the
remaining 2,023 participants reporting 2 or more asymptomatic episodes and who did not
did not have a follow-up examination, a 4.4% probability of false negatives was assumed.
(The 534 participants who reported both asymptomatic and symptomatic episodes during
follow-up were excluded from these calculations on the grounds that their symptomatic
episodes initiated a follow-up examination, thereby allowing for an observed event of
TMD.) This yielded an expected number of 110 participants with false-negative
asymptomatic episodes. When these cases were added to the 260 observed cases, the
imputed incidence rate increased to 5.0% per annum.
Discussion
Despite adopting rigorous follow-up procedures in this prospective cohort study, participants
were lost to follow-up and methods used to enumerate cases of first-onset TMD were
imperfect. Furthermore, quality assessment of examination data suggested that TMD case
classifications recorded by 1 examiner were dubious, notwithstanding extensive training and
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calibration and excellent interexaminer reliability. Conventional methods of complete case
analysis, which use only the observed data, ignore potential biases created by these
problems. Hence, 2 analytic strategies were used to assess the degree of bias. Hot-deck
multiple imputation, which accounted for complete loss to follow-up, yielded identical
overall incidence and generally similar or slightly attenuated hazard ratios compared to
complete-case analysis, suggesting that loss to follow-up was not a serious source of bias. A
2-stage, multiple-imputation procedure addressed problems arising from nonexamination—
or from dubious examination—of symptomatic episodes. The overall annual incidence rate
of 3.9% was slightly greater than the rate of 3.5% from the complete-case analysis, and
although differences in hazard ratios were small, both attenuation and amplification was
observed. The problem of false-negatives in follow-up questionnaires could be evaluated
only using single imputation, with the results suggesting that the true incidence rate in the
cohort might be as high as 5.0% per annum. Taken as a whole, these findings suggest that a
small, though not ignorable, amount of bias was created by missing or dubious data from
follow-up. Although the bias did not appreciably alter “bottom line” statistical conclusions
for the few risk factors investigated here, it is prudent to consider multiply-imputed findings
when evaluating the large number of risk factors under investigation in this study.
Study participants’ duration of follow-up in this study varied not only because of loss to
follow-up, but also because of the study design: a single census date was used for
participants enrolled over a period of more than 2 years. A conventional method to account
for differential periods of follow-up is to express incidence as the rate of occurrence, rather
than the proportion of people who develop the condition. The incidence rate is also labeled
the “force of morbidity”20 because it considers both the development of a condition and the
rapidity of onset. Furthermore, incidence rate ratios provide an intuitive measure of the
magnitude of association between hypothesized risk factors and TMD incidence. Hazard
ratios provide a good approximation of the incidence rate ratio and can be modeled, with
few assumptions, using Cox regression models. In this analysis, the principal statistical
assumption of proportional hazards was satisfied for the large number of putative risk
factors assessed.
A more serious concern is the possibility that loss to follow-up might occur differentially
according to putative risk factors, thereby biasing estimates. The 42% rate of complete
follow-up in this study was within the range reported for other, population-based studies that
have used multiple follow-up assessments to enumerate incidence of pain. In the UK study
of back pain, 30% of enrollees completed all 6 of the intended follow-up questionnaires,8
whereas in the U.S. study of 4 types of pain in adolescents, 64% completed all 11 of the
intended follow-up questionnaires.9 In principle, associations from complete-case analysis
of such data are more biased than estimates from imputed data sets that appropriately
account for missing data.22 Multiple imputation is a favored method for many types of data,
although imputation of the outcome measure in time-to-event data creates particular
challenges when the data are to be analyzed with Cox regression models,4 as in this setting.
The 2-stage method of multiple imputation was developed to deal with those challenges.
When evaluated in simulation studies, the method was markedly superior to complete case
analysis with respect to bias, coverage, and confidence interval width under various
assumptions regarding the pattern of missing data and characteristics of variables used for
imputation.2 Using the data from this cohort, the method produced slightly greater estimates
of the incidence rate than the complete-case analysis. Differences in hazard ratios were
likewise small, although compared to the complete-case analysis, the estimates moved in
varying directions, either toward or away from the null, according to the risk factor being
analyzed. This is consistent with the findings of an earlier study by Cook and Kosorok4 who
found that there is little loss in efficiency when up to 50% of possible events in a prospective
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cohort study are unadjudicated. Nevertheless, both the simulation findings and the current
sensitivity analysis indicated some bias in estimates from complete-case analysis, which,
though usually small in magnitude, should not be ignored when evaluating putative risk
factors. For that reason, accompanying papers in this volume report both unimputed
(complete-case) and imputed findings that account for missing or dubious data from follow-
up examinations.
The problem of dubious case classifications by 1 examiner was unexpected given the
intensity of examiner training conducted prior to study commencement and annually
thereafter. Furthermore, the examiner and the study’s reference examiner had excellent
levels of agreement in annual studies of interexaminer reliability. Problems were first
suspected during annual data quality assessment, and the findings were reported to the
OPPERA Scientific Advisory Committee in December 2008. The Committee advised the
investigators to investigate the problem further using more detailed information as it
accrued. By the time the problem was confirmed and reported to the Committee at its
December 2009 meeting, the examiner had stopped working in the study. The Committee
then advised the investigators to develop strategies for analyses that acknowledged and
addressed the problem. Accordingly, this paper has focused on the problem and used the
second method of multiple imputation2 to address it.
As noted above, frequent follow-up assessments are needed to properly enumerate incidence
of pain over a period of years. Because reexamination at that frequency for all subjects is not
feasible in population studies, high-quality screening mechanisms are required. The
questions in the quarterly health updates that screened for orofacial pain had excellent test-
retest reliability. Based on the combination of sensitivity (90%) and specificity (56%), they
also had good validity that exceeded a previous study of adults.23 In formulating the
screening questions, greater emphasis was given to specificity than to sensitivity on the
grounds that false positives (which reduce sensitivity) would be identified during
examination and therefore not counted as incident cases. Nonetheless, future studies should
consider using a new screening questionnaire for TMD, developed after commencement of
OPPERA, which has better sensitivity and specificity.13
Despite the small proportion of false negatives in this study, it was not ignorable because the
majority of participants reported no symptoms throughout the study. Indeed, the estimated
incidence rate increased to 5% per annum with single imputation to account for the false
negatives. Ideally, multiple imputation of these false-negative events would allow sensitivity
analysis to determine the effects on hazard ratios. However, there were too few false
negatives to permit such analysis.
Although loss to follow-up in prospective cohort studies is potentially a serious threat, the
study design has inherent strengths for etiologic research, including its focus on prognosis
and its determination of a temporal association between putative causes and effects.
Furthermore, prospective cohort studies are less prone to selection bias, which is a particular
problem in case-control studies of pain.26 For example, if a case-control study recruited
potential cases from among patients seeking health care, whereas controls were recruited
from the community, cases likely would have greater odds of health insurance coverage. The
resulting odds ratio would spuriously suggest that recent health insurance increased the risk
of TMD. Furthermore, other spurious associations probably would be seen for
characteristics associated with health insurance. In contrast, prospective cohort studies
enumerate TMD during follow-up examinations using the same procedures for all enrollees,
regardless of baseline characteristics such as health insurance. This independence between
putative risk factors and procedures used in enumerating cases vastly diminishes the
potential for selection bias, which is a major concern in case-control studies.
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Results from this study can be generalized only to the target population of 18- to 44-year-
olds with no significant history of TMD symptoms and no serious health conditions. The age
range is one in which U.S. population surveys19,30,32 show an age-associated increase in
prevalence, peaking in the fifth decade. It effectively excludes postmenopausal women
whose risk of TMD likely is influenced by changes in reproductive hormones.21 In a
separate paper in this volume,33 we discuss the implications of this age restriction when
comparing OPPERA results with other cohort studies. Another caveat is that participants
were not a probability sample drawn at random from the population, but rather volunteers
recruited by advertisements at 4 U.S. study sites. Elsewhere,32 we have reported that the
distribution of sociodemographic characteristics in this OPPERA cohort is similar to some,
although not all, benchmarks from the U.S. population census. We therefore concluded that
findings are broadly applicable to major demographic groups in the United States.
Another important caveat about generalizability is that this study focused on first-onset
TMD in an initially symptom-free cohort. Recurrent bouts of TMD were not enumerated,
and hence the total burden of TMD in the population was underestimated. Conversely,
though, some participants might have been enrolled incorrectly, having forgotten about
episodes of TMD experienced many years before they were screened for eligibility. Indeed,
in a separate study of TMD symptoms in this cohort,34 we found that one third reported
orofacial pain for ≥5 days per month in at least 1 month during follow-up and we speculated
that some individuals likely had forgotten about self-limiting episodes of pain that occurred
many years prior to enrollment in a study.
In summary, this paper has documented 3 critical methodological components of the
OPPERA prospective cohort study: 1) mindful of the intermittent nature of pain, the study
was designed with quarterly follow-up assessments to optimize enumeration of first-onset
TMD; 2) particular attention was paid to data quality, including annual examiner training
and procedures to monitor reliability and validity of the study’s main outcomes; and 3)
rigorous statistical methods were adapted to evaluate and reduce potential biases that can
occur because of the inevitable problem of missing follow-up data. The findings support the
study’s validity for the purpose of investigating the etiology of first-onset TMD and provide
the foundation for other papers investigating risk factors hypothesized in the OPPERA
project.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Flowchart of enrollment and follow-up: OPPERA prospective cohort study, 2006 to 2011.
*Follow-up data collection continued after examination of people who did not have TMD.
Hence, individuals could have more than 1 follow-up examination prior to censoring or
developing TMD. †Follow-up data collected after examiner-classified TMD were not used
in this analysis.
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Tests of proportional hazards assumption: OPPERA prospective cohort study, 2006 to 2011.
Quantile-quantile plots of P values from 251 tests of proportional hazards assumption. FDR,
false-discovery rate.
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Tests of association between baseline characteristics and loss to follow-up: OPPERA
prospective cohort study, 2006 to 2011. Quantile-quantile plots of P values from tests of
association between 521 people completely lost to follow-up and 2,737 people who
completed 1 or more follow-up questionnaires. Dependent variables were 28 measures of
pain sensitivity (A), 27 psychological characteristics (B), 51 measures of autonomic function
(C), and 42 clinical characteristics (D).
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Table 2








All people 721 478 66.3
Demographics and study site
 Age when enrolled, y
  18–24 250 164 65.6
  25–34 184 120 65.2
  35–44 287 194 67.6
  P value* .900
 Gender
  Female 450 293 65.1
  Male 271 185 68.3
  P value .490
 Race/ethnicity
  White 325 206 63.4
  Black or African American 318 223 70.1
  Asian 19 13 68.4
  Hispanic 30 20 66.7
  Other or unstated 29 16 55.2
  P value .978
 Study site
  Baltimore, MD 303 184 60.7
  Buffalo, NY 153 106 69.3
  Chapel Hill, NC 113 87 77.0
  Gainesville, FL 152 101 66.5
  P value .009
Risk predictors recorded at
  baseline
 No. of tender body sites
  None 346 238 68.8
  1–3 216 140 64.8
  ≥4 159 100 62.9
  P value .416
 Stroop-Pain Δ MAP, mmHg
  <–2 273 174 63.7
  −2 to +2 205 136 66.3
  >+2 121 90 74.4
  P value .291
 Pressure pain threshold:
  trapezius, kPa
  <275 244 155 63.5





















  275–<440 240 170 70.8
  ≥440 227 145 63.9
  P value .671
 Perceived Stress Scale
  <12 168 105 62.5
  12–<18 243 159 65.4
  ≥18 307 212 69.1
  P value .071
Risk predictors recorded in
  quarterly health update
 Number of nonspecific
  orofacial symptoms
  None 188 134 71.3
  1 210 133 63.3
  2 162 116 71.6
  ≥3 161 95 59.0
  P value .109
 Time since enrollment, mo
  <12 180 143 79.4
  11–<20 194 137 70.6
  20–<30 163 113 69.3
  ≥30 184 85 46.2
  P value <.001
*
P values are from score-statistic for Type III generalized estimating equation analysis of null hypothesis that percentage examined is equivalent
among subgroups. The generalized estimating equation model adjusted for clustering of symptom episodes within people.
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Table 3
Examination Outcomes Following Quarterly Health Updates: OPPERA Prospective Cohort Study, 2006 to
2011









Demographics and study site
 All people 478 49.2 338 92.6
 Age when enrolled, y
  18–24 164 57.9 151 90.1
  25–34 120 60.0 89 92.1
  35–44 194 35.1 98 96.9
  P value† <.001 .066
 Gender
  Female 293 51.2 217 91.7
  Male 185 45.9 121 94.2
  P value .326 .385
 Race/ethnicity
  White 206 58.7 183 90.2
  Black or African American 223 37.2 86 96.5
  Asian 13 69.2 37 100.0
  Hispanic 20 80.0 25 88.0
  Other or unstated 16 37.5 7 85.7
  P value <.001 nc
 Study site
  Baltimore, MD 184 28.8 95 95.8
  Buffalo, NY 106 61.3 102 94.1
  Chapel Hill, NC 87 32.2 46 95.7
  Gainesville, FL 101 88.1 95 86.3
  P value <.001 .137
Risk predictors recorded at baseline
 No. of tender body sites
  None 238 35.7 154 96.8
  1–3 140 50.7 92 92.4
  ≥4 100 79.0 92 85.9
  P value <.001 .016
 Stroop-Pain Δ MAP, mmHg
  <–2 174 49.4 93 91.4
  −2 to +2 136 52.9 103 90.3
  >+2 90 51.1 79 93.7
  P value .871 .698
 Pressure pain threshold: trapezius, kPa
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  <275 155 47.7 122 92.6
  275–<440 170 53.5 99 91.9
  ≥440 145 45.5 114 93.9
  P value .445 .856
 Perceived Stress Scale
  <12 105 57.1 118 94.1
  12–<18 159 49.1 135 93.3
  ≥18 212 45.3 83 89.2
  P value .172 .469
Risk predictors recorded at QHU
 Number of nonspecific orofacial symptoms
  None 134 39.6 273 95.6
  1 133 38.3 33 87.9
  2 116 56.0 18 94.4
  ≥3 95 69.5 14 42.9
  P value <.001 .022
 Time since enrollment, mo
  <12 143 60.8 69 95.7
  11–<20 137 53.3 93 91.4
  20–<30 113 39.8 88 89.8
  ≥30 85 35.3 88 94.3
  P value <.001 .441
 Examiner at follow-up
  Examiner 4 75 100.0 34 76.5
  Other examiners at same site as 4 24 50.0 60 91.7
  Examiners at other sites 379 39.1 244 95.1
  P value nc .049
NOTE. nc = P value not calculated because of 0% or 100% cell.
*
Symptomatic examinations were those conducted following a quarterly health update in which orofacial pain symptoms were reported.
Asymptomatic examinations were those conducted following a quarterly health update in which no orofacial symptoms were reported. PPV =
positive predictive value of the quarterly health update screening questions regarding orofacial pain. NPV = negative predictive value of the same
screening questions.
†
P values are from score-statistic for Type III generalized estimating equation analysis of null hypothesis that examination outcome is equivalent
among subgroups. The generalized estimating equation model adjusted for clustering of examinations within people.
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Table 4
Interexaminer Reliability of 7 Examiners: OPPERA Prospective Cohort Study, 2006 to 2011
Date Examiner Number ofPaired Examinations
Kappa
(95% CLs)
February 2006 7 24 .83 (.60, 1.00)
4 24 .92 (.74, 1.00)
5 24 .92 (.74, 1.00)
April 2006 5 16 1.00 n/a)†
6 16 1.00 n/a)
October 2006 4 15 1.00 n/a)
May 2007 7 15 1.00 n/a)
June 2007 7 16 1.00 n/a)
4 16 1.00 n/a)
5 16 1.00 n/a)
6 16 1.00 n/a)
February 2009 7 20 1.00 n/a)
4 20 1.00 n/a)
2 19 .82 (.24, 1.00)
6 20 1.00 n/a)
June 2010 7 20 .89 (.74, 1.00)
3 20 .89 (.77, 1.00)
6 20 .89 (.58, 1.00)
1 15 1.00 n/a)
October 2011 7 20 1.00 n/a)
1 20 1.00 n/a)
3 20 1.00 n/a)
6 20 1.00 n/a)
*
Reliability of TMD case classification was assessed in paired examinations of volunteers who were not study participants: one of the paired
examinations was conducted by the OPPERA study-site examiner and the other paired examination was conducted by the OPPERA reference
examiner.
†
95% CLs are not applicable for kappa values of 1.00.
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Table 5






Imputation for People Who Were


















All people 2,737 3.5 3.2, 3.9 3,258 3.5 3.2, 3.9 2,737 3.9 3.5, 4.3
Age when enrolled, y
 18–24 1,421 2.9 1,706 3.0 1,421 3.1
 25–34 736 3.8 1.34(1.01, 1.79) 860 3.8 1.28 (.97, 1.70) 736 4.1 1.32 (.98, 1.78)
 35–44 580 4.7 1.66(1.23, 2.24) 692 4.6 1.56(1.17, 2.09) 580 5.5 1.76(1.30, 2.39)
Gender
 Female 1,107 3.1 1,396 3.3 1,107 3.3
 Male 1,630 3.8 1.21 (.94, .15) 1,862 3.7 1.13 (.88, .33) 1,630 4.2 1.27 (.97, .08)
Race/ethnicity
 White 1,448 3.3 1,637 3.4 1,448 3.7
 Black/African 766 4.7 1.39(1.06, 1.81) 1,012 4.5 1.32 (1.01, 1.72) 766 5.4 1.48(1.13, 1.94)
  American
 Asian 256 1.4 .40 (.20, .78) 299 1.6 .46 (.24, .88) 256 1.6 .42 (.21, .85)
 Hispanic 178 3.9 1.16 (.72, 1.88) 211 3.8 1.12 (.70, 1.80) 178 3.4 .90 (.51, 1.61)
 Other or unstated 89 2.8 .87 (.41, 1.87) 99 2.9 .89 (.42, 1.88) 89 3.2 .86 (.40, 1.82)
Study site
 Buffalo, NY 693 3.9 797 3.9 693 4.9
 Baltimore, MD 574 4.2 1.07 (.75, 1.51) 768 4.2 1.07 (.76, 1.50) 574 5.3 1.07 (.76, 1.48)
 Gainesville, FL 765 4.8 1.25 (.93, 1.70) 878 4.5 1.21 (.89, 1.63) 765 4.2 .83 (.61, 1.15)
 Chapel Hill, NC 705 1.4 .38 (.25, .58) 815 1.7 .46 (.30, .70) 705 1.8 .36 (.24, .54)
No. of tender body sites
 None 1,301 2.6 1,584 2.8 1,301 3.1
 1–3 682 4.1 1.62 (1.20, 2.20) 808 4.1 1.50(1.12, 2.01) 682 4.5 1.43 (1.05, 1.95)
 ≥4 754 4.5 1.77 (1.32, 2.37) 866 4.4 1.62 (1.22,2.16) 754 4.6 1.48(1.10, 1.99)
Stroop-Pain Δ
   MAP, mmHg
 <–2 814 4.4 982 4.2 814 4.9
 −2 to +2 774 3.9 .90 (.67, 1.21) 911 3.9 .91 (.68, 1.22) 774 4.2 .85 (.63, 1.15)
 >+2 625 2.9 .67 (.48, .94) 716 2.9 .70 (.50, .97) 625 2.9 .59 (.41, .86)
Pressure pain threshold:
  trapezius, kPa
 <275 922 2.9 1,057 3.0 922 3.3
 275–<440 897 4.0 1.39(1.03, 1.88) 1,089 4.0 1.33 (.99, 1.79) 897 4.1 1.23 (.90, 1.69)
 ≥440 895 3.4 1.18 (.86, 1.62) 1,082 3.5 1.18 (.86, 1.61) 895 4.1 1.22 (.89, 1.67)
Perceived Stress Scale
 <12 914 2.5 1,035 2.7 914 2.9


















Imputation for People Who Were


















 12–<18 962 3.3 1.27 (.93, 1.75) 1,132 3.3 1.25 (.91, 1.71) 962 3.6 1.25 (.90, 1.73)
 ≥18 847 5.1 1.96(1.44, 2.66) 1,064 4.8 1.77(1.31,2.40) 847 5.5 1.97 (1.43, 2.70)
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